ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Japan Inc.'s overseas acquisitions hit record

Companies bought nearly $100bn worth of foreign businesses in fiscal 2016

Japanese acquisitions of overseas businesses reached a record in fiscal 2016.

TOKYO -- Foreign acquisitions by Japanese companies jumped about 30% in the fiscal year ended Friday to a record 10.91 trillion yen ($97.9 billion), as rock-bottom interest rates at home allowed businesses to pursue larger deals than in the past.

The number of acquisitions also climbed 6% to an all-time high of 627, according to mergers and acquisitions consultancy Recof.

The biggest deal of fiscal 2016 was SoftBank Group's roughly 24 billion pound ($30.1 billion at current rates) purchase of British chip designer ARM Holdings, which topped the record for any acquisition of a foreign company by a Japanese business. SoftBank secured the necessary funds through bond issuances and other means.

Beverage maker Asahi Group Holdings bought beer-making operations in Eastern Europe for 7.3 billion euros ($7.77 billion at current rates), in a bid to gain local recognition and sales networks. The company aims to increase the proportion of sales and profit it makes abroad.

"Given low interest rates and a shrinking population at home, business leaders are seeking opportunities for mergers and acquisitions in the U.S. and Europe," said Kensaku Bessho of Mitsubishi UFJ Morgan Stanley Securities.

Such concerns also pushed many companies with little experience in foreign acquisitions to pursue deals. Heavy equipment maker Komatsu agreed to buy Joy Global, a U.S.-based manufacturer of mining equipment, for about $2.89 billion, in what will be the company's largest acquisition yet. "We'll be able to establish a complementary relationship between products that we ourselves do not produce," said Komatsu President and CEO Tetsuji Ohashi.

Generic-drug maker Nichi-iko Pharmaceutical hopes to become one of the world's top 10 players through its acquisition of U.S.-based Sagent Pharmaceuticals. The $736 million deal is the largest on record for a Japanese generic-drug maker buying a company abroad.

One manufacturer in Japan's Chubu region around Nagoya is also considering foreign acquisitions in hopes of making inroads in growing markets.

"Investors are urging companies to review their business structure and improve their capital efficiency," said Shinsuke Tsunoda of Nomura Securities.

Experts say only about 20% of foreign mergers and acquisitions succeed. If the new overseas subsidiaries do not perform as well as expected, their Japanese parents will be forced to book a goodwill impairment. Toshiba, for example, ended up with massive losses over its U.S.-based nuclear subsidiary Westinghouse Electric. Those looking into acquisitions need a strategy for managing the people and operations at their would-be subsidiaries in order to quickly establish synergies.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media